“This is a strategic appointment as we prepare for the next phase of Hansa’s growth. Mr Röök is a highly qualified and proven business development leader with deep expertise in complex transactions, a strong strategic mindset, and a broad global network. He will play a key role as we advance our pipeline and pursue new strategic opportunities. His addition strengthens our capabilities further at a pivotal stage for the company,” says Renée Aguiar-Lucander, CEO of Hansa Biopharma.

Fredrik Röök

Fredrik Röök brings more than 20 years of experience in business development, licensing, and strategic transactions across the global life science industry. He joins Hansa from AstraZeneca, where he served as Senior Director, Global Business Development, leading complex partnering activities including M&A, in- and out-licensing, divestments, and strategic collaborations. He has a strong track record of executing transactions across all stages, from early innovation to commercial assets, across pharma, biotech, and venture-backed environments. Fredrik Röök holds an M.Sc. in Pharmacy from the University of Gothenburg and an MBA from Simon Fraser University.